1 |
Ahn, C. (1998). An evaluation of phase I cancer clinical trial designs, Statistics in Medicine, 17, 1537-1549.
DOI
|
2 |
Chevret, S. (1993). The continual reassessment method in cancer phase I clinical trials: A simulation study, Statistics in Medicine, 12, 1093-1108.
DOI
ScienceOn
|
3 |
Dixon, W. J. and Mode, A. M. (1948). A method for obtaining and analyzing sensitivity data, Journal of the American Statistical Association, 43, 109-126.
DOI
ScienceOn
|
4 |
Faries, D. (1994). Practical modications of the continual reassessment method for phase 1 cancer clinical trials, Journal of Biopharmaceutical Statistics, 4, 147-164.
DOI
ScienceOn
|
5 |
Goodman, S. N., Zhurak, M. L. and Piantadosi, S. (1995). Some practical improvements in the continual reassessment method for phase I studies, Statistics in Medicine, 14, 1149-1161.
DOI
ScienceOn
|
6 |
Kang, S. H. (2002). Investigation on the modied continual reassessment method in phase I clinical trial, Journal of Applied Statistics, 15, 323-336.
|
7 |
Kim, D. U. and Kil, S. K. (2009). Precision and safety comparison for SM, CRM and ATD in phase I clinical trials, Communications of the Korean Statistical Society, 16, 51-65.
과학기술학회마을
DOI
ScienceOn
|
8 |
Korn, E. L., Midthune, D., Chen, T. T., Rubinstein, L. V., Christian, M. C. and Simon, R. M. (1994). A comparison of two phase I trial designs, Statistics in Medicine, 13, 1799-1806.
DOI
ScienceOn
|
9 |
O'Quigley, J. and Chevret, S. (1991). Method for dose nding studies in cancer clinical trials: A review and results of a Monte Carlo study, Statistics in Medicine, 10, 1647-1664.
DOI
ScienceOn
|
10 |
Storer, B. E. (1989). Design and analysis of phase I clinical trials, Biometrics, 45, 925-937.
DOI
ScienceOn
|
11 |
Park, I. H. (1999). The estimation of maximal tolerated dose in sequential phase I clinical trials, Department of Biostatistics, The Catholic University of Korea, Biostatistics Master's Thesis.
|